Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Realty & metal, biggest losers
Thu, 30 Jan 01:30 pm

After opening in the red on news of Fed tapering, Indian share markets continued to slip deeper in the red in the post-noon trading session. All the sectoral indices are trading in the red with realty, metal and banking stocks being the biggest losers.

BSE-Sensex is down 239 points and NSE-Nifty is trading 74 points down. BSE Mid Cap is trading 1.2% down and BSE Small Cap index is trading down by 1.4%. The rupee is trading at 62.6 to the US dollar.

As per a leading financial daily, Securities Exchange Board of India (SBI) is considering a proposal to make it mandatory for all listed Indian companies to have a succession plan. The implementation of the proposal is to ensure that the investing community is not adversely impacted by the demise, exit or poor performance of the leader at the helm of affairs of the company. Reportedly, most Indian companies do not have a formal succession plan for appointment to board or senior management positions.

Most of the Indian pharma stocks are trading in the red with Dishman Pharma and J B Chemicals leading the pack of losers. Aurobindo Pharma and Lupin are among the few stocks trading in the green. As per a leading business daily, medicines manufactured by Ranbaxy Laboratories have been cleared by the UK drug regulator. This comes in the backdrop of the US Food and Drug Administration (USFDA) earlier banning medicines manufactured at the company's Toansa plant in Punjab. The Medicines and Healthcare Products Regulatory Agency (MHRA) has said that there is no evidence that medicines in UK are defective and so people should continue to take their medicines accordingly. MHRA has also said that it is working with the other international regulatory partners as well as the regulator of European Union to determine the implications of USFDA findings for UK. The USFDA had found several shortcomings in its latest inspection of the Taonsa plant such as presence of flies in sample preparation and broken storage cabinets as well as no proper control to prevent unauthorized access to data files and folders. Ranbaxy's stock is trading down 2.9%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Realty & metal, biggest losers". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.